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Abstract The accurate analytical measurement of binding af-
finities of polyclonal antibody in sera to heroin, 6-
acetylmorphine (6-AM), and morphine has been a challenging
task. A simple nonradioactive method that uses deuterium-
labeled drug tracers and equilibrium dialysis (ED) combined
with ultra performance liquid chromatography/tandem mass
spectrometry (UPLC/MS/MS) to measure the apparent dissoci-
ation constant (Kd) of antibodies to 6-AM and morphine is
described. The method can readily detect antibodies with Kd
in the low nanomolar range. Since heroin is rapidly degraded in
sera, esterase inhibitors were included in the assay, greatly re-
ducing heroin hydrolysis. MS/MS detection directly measured
the heroin in the assay after overnight ED, thereby allowing the
quantitation of % bound heroin in lieu of Kd as an alternative
measurement to assess heroin binding to polyclonal antibody
sera. This is the first report that utilizes a solution-based assay to
quantify heroin-antibody binding without being confounded by
the presence of 6-AM and morphine and to measure Kd of
polyclonal antibody to 6-AM. Hapten surrogates 6-AcMorHap,
6-PrOxyHap, MorHap, DiAmHap, and DiPrOxyHap coupled
to tetanus toxoid (TT) were used to generate high affinity anti-
bodies to heroin, 6-AM, and morphine. In comparison to com-
petition ED-UPLC/MS/MS which gave Kd values in the
nanomolar range, the commonly used competition enzyme-
linked immunosorbent assay (ELISA) measured the 50 % inhi-
bition concentration (IC50) values in the micromolar range. De-
spite the differences in Kd and IC50 values, similar trends in
affinities of hapten antibodies to heroin, 6-AM, and morphine
were observed by both methods. Competition ED-UPLC/MS/
MS revealed that among the five TT-hapten bioconjugates, TT-
6-AcMorHap and TT-6-PrOxyHap induced antibodies that
bound heroin, 6-AM, and morphine. In contrast, TT-MorHap
induced antibodies that poorly bound heroin, while TT-
DiAmHap and TT-DiPrOxyHap induced antibodies either did
not bind or poorly bound to heroin, 6-AM, and morphine. This
simple and nonradioactive method can be extended to other
platforms, such as oxycodone, cocaine, nicotine, and metham-
phetamine for the selection of the lead hapten design during
substance abuse vaccine development.
Keywords Heroinhapten .CompetitionELISA .Equilibrium
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Introduction
Therapeutic vaccines to drugs of abuse obstruct the psycho-
active effects of the drugs by inducing antibodies that bind and
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prevent the drugs from traversing the blood-brain barrier [1,
2]. The development of a heroin vaccine presents a particular
challenge because heroin rapidly metabolizes in serum to 6-
acetylmorphine (6-AM) and morphine [3]. For effective se-
questration of the drugs, hapten bioconjugate vaccines must
induce both high titer and high affinity antibodies not only to
heroin, but also to 6-AM and morphine [4, 5]. Vaccines to
drugs of abuse have been increasingly explored as an alterna-
tive treatment for drug addiction. Vaccines have been effica-
cious in blunting the physiological effects of heroin and other
abused drugs in animals. Several studies have demonstrated
that the affinity and titer of the induced antibodies [1, 2] and
hapten density [6, 7] of the hapten-protein conjugates are crit-
ical components of vaccine efficacy. There is a general agree-
ment that enzyme-linked immunosorbent assay (ELISA) can
readily and reliably quantify antibody titer [8–11]. In contrast,
the measurement of hapten antibody affinity to heroin and its
metabolites, as well as other substances of abuse, is generally
estimated by competition ELISA [12, 13]. Concerns have
been raised that competition ELISA does not accurately mea-
sure the antibody affinity [7, 14, 15]. Several of these concerns
are as follows: (1) In serum, heroin is rapidly deacetylated to
6-AM and morphine by blood esterases (Fig. 1a) [16–20]. The
enzymatic degradation of heroin during the assay changes the
concentration of the drugs, and therefore, the calculated affin-
ity constant may not be for heroin per se but for mixture of
drugs. (2) The accuracy of ELISA is dependent on the hapten
density of the coating agents [21]. (3) There is a localized high
concentration of the hapten coated on the well, which allows
for both arms of the immunoglobulin G (IgG) to bind to the
well resulting in the requirement of high concentrations of
competitive inhibitor to prevent antibody binding. (4) Similar-
ly, the affinity of the antibody to the immunizing hapten is
most likely higher than its affinity to the competitive inhibitor
resulting in the further requirement of high concentrations of
the competitive inhibitor. Based on these issues, a new meth-
odology for the accurate measurement of the affinity of anti-
bodies to drugs of abuse needs to be developed.
Equilibrium dialysis (ED) is the standard method for mea-
suring the affinity of proteins to small molecules [22]. How-
ever, conventional ED between polyclonal sera and drugs
cannot be employed to calculate the apparent dissociation
constant (Kd) because the antibody concentration is unknown.
To circumvent this problem, a competition ED utilizing radio-
active tracers as competitive inhibitors is often employed
(Müller’s method) [23]. For the antibodies induced by heroin
vaccines, the use of radioactive tracers to study heroin-
antibody binding presents two main challenges. First, radio-
active heroin and 6-AM are not commercially available. Sec-
ond, the short half-life of heroin and its metabolites in sera is
not compatible with the long equilibration time required for
ED. We posit that (1) by using an alternative probe and detec-
tion system and (2) by identifying assay conditions that pre-
vent the degradation of heroin and its metabolites during ED,
binding affinities of heroin, 6-AM, and morphine to polyclon-
al antibody could be assessed.
Liquid chromatography coupled with mass spectrometry is
a valid approach for the detection of drug metabolites in bio-
logical fluids and could be used to quantify drugs that are

























































































Fig. 1 Heroin metabolites and
heroin haptens. Degradation of
heroin in humans (a). Heroin
haptens with different linker
attachment points (b). Haptens
were coupled to tetanus toxoid
(TT) to yield the TT-hapten
bioconjugates
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nonradioactive deuterium-labeled drug tracers (D3-tracers),
such as D3-heroin, D3-6-AM, and D3-morphine, instead of
radioactive analogs could be used as tracers in ED. In these
D3-tracers, the methyl group of nitrogen is replaced by CD3
(see Electronic supplementary material (ESM) Fig. S1). Since
the mass difference between the D3-tracer and corresponding
unlabeled drug is significant (Δmass=3.02 amu), mass spec-
trometry will be able to discriminate these structurally similar
molecules. From an analytical standpoint, the obvious advan-
tage of using D3-tracer/liquid chromatography/mass spec-
trometry as a probe/detection system over radioactive tracer/
scintillation counter and unlabeled drug/enzymatic colorimet-
ric method (ELISA) is that the former can evaluate the integ-
rity of the probe during the assay condition and thereby an
unambiguous affinity constant can be determined. We herein
report a nonradioactive competition ED coupled with ultra
performance liquid chromatography tandem mass spectrome-
try (UPLC/MS/MS) method that we used to assess the accu-
rate binding affinities of heroin hapten antibodies to 6-AM
and morphine. Using this method, (1) we demonstrate that
different heroin hapten designs can induce antibodies of vary-
ing affinities (Fig. 1b), and (2) we substantiate that the con-
cerns raised about competition ELISA are valid and that the
simple methodology of competition ED-UPLC/MS/MS
should be used to more accurately measure substance abuse
vaccine-induced antibody affinity for the abused substance.
Materials and methods
Tritylmercaptopropionic acid (≥98 %) was acquired from
Chem-Impex International (Wood Dale, IL, USA). Chemical
reagents and solvents were ACS reagent grade, obtained from
Sigma-Aldrich Chem. Co., and were used without further puri-
fication. N-hydroxysuccinimide (NHS, 98%), acetic anhydride
(Ac2O, ≥99 %), 4-(dimethylamino)pyridine (DMAP, ≥99 %),
formic acid for mass spectrometry, tetraisopropyl
pyrophosphoramide (iso-OMPA), and bis(4-nitrophenyl) phos-
phate (BNPP, 99%)were purchased from Sigma-Aldrich (Saint
Louis, MO, USA). Calibrated solutions (1 mg/mL) of
heroin.HCl.H2O, D3-heroin.HCl, 6-AM.HCl, D3-6-AM.HCl,
morphine.H2O, and D3-morphine that were used for ED were
purchased from Lipomed (Cambridge, MA, USA). Calibrated
solutions used were Certified Reference Materials. Optima™
LC/MS grade ammonium formate (NH4HCOO), methanol
(MeOH), acetonitrile (ACN), and water (H2O) were purchased
from Fischer Scientific (Suwanee, GA, USA). Anti-morphine
antibody (ab1060) was purchased from Abcam (Cambridge,
MA, USA). Single-use equilibrium dialysis plate with 48 in-
serts was purchased from Thermo Fisher Scientific (Waltham,
MA,USA). An insert (dialysis cassette) contains a sample and a
buffer chamber separated by a membrane with 12 K molecular
weight cutoff. Screw neck total recovery vial with
polytetrafluoroethylene/silicone septa was purchased from
Waters (Cambridge, MA, USA). Dulbecco’s phosphate
buffered saline (DPBS, 10 mM Na2HPO4, 1.8 mM
KH2PO4, 2.7 mM KCl, 137 mM NaCl, pH 7.4) that was
used for equilibrium dialysis was purchased from Quality
Biological Inc. (Gaithersburg, MD, USA).
Synthesis of 6-AcMorHap
6-AcMorHap was synthesized in eight steps (Fig. 2). Triftylated
hydromorphone (2), 3-desoxydihydromorphinone (3), 1-chloro-
3-desoxydihydromorphinone (4), and 1-chloro-3-nitro-
dihydromorphinone (5) were synthesized sequentially from
hydromorphone (1) using the procedure described by Li et al.
[25]. The detailed synthesis and analytical characterization of 1-
chloro-3-nitro-dihydromorphine (6), 3-amino-dihydromorphine
(7), 3-tritylthiopropanamide-dihydromorphine (9), and 6-
AcMorHap were described in the ESM. The structure of 6-
AcMorHap was confirmed by its 1H and 13C nuclear magnetic
resonance (NMR) spectra (see ESM Figs. S2 and S3).
Equilibration of D3-morphine and morphine
In a competition ED, the competitive inhibitor is added on one
side of the cassette (buffer chamber) and the tracer to the other
side (sample chamber). The two chambers are allowed to
reach equilibrium prior to measurements. Equilibration time
is the incubation period where ∼50 % of competitive inhibitor
and tracer are located in both the buffer and sample chambers.
Morphine (300 μL, 1333.3 nM in DPBS) and D3-morphine
(100 μL, 5 nM in DPBS) were added into the buffer and
sample chambers, respectively. Triplicates were allotted for
each time interval: 3, 6, 12, and 24 h. The dialysis plate was
covered with sealing tape and incubated at 4 °C/300 rpm on a
ThermoMixer® C apparatus (Eppendorf AG, Hamburg, Ger-
many). At a given time point, equal volumes (90 μL) were
pipetted from both the sample and buffer chambers. The sam-
ples were subsequently placed in separate total recovery vials
containing 1 μL of 10 % aqueous formic acid for UPLC/MS/
MS analysis. The % drug in the sample and buffer chambers
was calculated using the formula:
%drugsample or bu f fer chamber ¼
drug½ sample or bu f f er chamber
drug½ sample chamber þ drug½ bu f fer chamber
 100
where [drug]sample chamber and [drug]buffer chamber are the con-
centrations of the drug in the sample and buffer chambers,
respectively.
Stability of heroin and its metabolites
For accurate measurement ofKd, the drugs must remain stable
during the equilibration time. The stability of heroin and its
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metabolites was assessed at different dilutions of the mouse
sera. An aliquot of the drug (5 nM, 400 μL in DPBS) was
treated with different dilutions (1:25, 1:50, 1:100, 1:200, and
1:400) of mouse sera. The reaction mixture was incubated at
4 °C and the amount of drug was monitored at a given time
interval using UPLC/MS/MS. The % remaining drug was
calculated using the formula:
% remaining drug ¼ drug½ t
drug½ initial
 100
where [drug]t is the concentration of the drug at time t and
[drug]initial is the initial concentration of the drug.
Competition equilibrium dialysis of monoclonal antibody
Anti-morphine antibody (ab1060) is a mouse monoclonal an-
tibody, supplied as a protein G purified antibody (∼2 mg/mL).
The approximate molecular weight of the IgG is 155 kDa.
Based on this information, the antibody concentration of the
stock solution is ∼12.9 μM. ab1060 has a reportedKd value of
2 nM, which was determined by proprietary ultraviolet-visible
(UV-VIS) absorption spectroscopy method that correlated ab-
sorbance with the concentration of the ligand-antibody com-
plex [26]. Samples for equilibrium dialysis were prepared by
diluting the stock solution in DPBS to yield 2.4, 4.8, and
9.6 nM. Inhibition studies were conducted in a single-use
equilibrium dialysis plate with inserts following manufac-
turer’s instruction. A 100-μL aliquot of ab1060 (2.4, 4.8,
and 9.6 nM) with a fixed amount of D3-morphine (Table 1)
was pipetted into the sample chamber, and a 300-μL aliquot of
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Fig. 2 Synthesis of heroin hapten
6-AcMorHap
Table 1 Affinity of monoclonal antibody ab1060 to morphine at
different concentrations of the antibody and D3-morphine
Antibody, nMa D3-morphine, nM
a b valuesb Dissociation constant
(Kd, nM)
c
9.6 5.0 0.94±0.014 0.11±0.01
4.8 5.0 0.78±0.012 0.72±0.05
2.4 5.0 0.41±0.007 1.96±0.17d
2.4 2.5 0.86±0.060 0.10±0.06
2.4 10 0.36±0.001 0.81±0.07
a Initial concentration of binding partners
b Fraction of D3-morphine bound to the monoclonal antibody in the ab-
sence of inhibitor
c All Kd values were calculated using Müller’s equation and are the mean
of triplicate determinations±standard deviation
d The affinity that is closest to the reported Kd value of 2 nM
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buffer chamber (1:400, vide infra). Morphine, which is the
competitive inhibitor, was prepared at different concentra-
tions. The total volume of the solution in the insert is
400 μL. The dialysis plate was covered with sealing tape
and incubated at 4 °C/300 rpm on a ThermoMixer® C appa-
ratus. After 24 h, equal volumes (90 μL) were pipetted from
both the sample and buffer chambers and placed in separate
total recovery vials containing 1 μL of 10 % aqueous formic
acid for UPLC/MS/MS analysis.
Competition equilibrium dialysis of anti-hapten sera
The preparation of anti-hapten sera and the strategy for con-
ventional and competition ED were described in the ESM.
Week 0 and week 9 sera were considered as negative and
anti-hapten sera, respectively. Anti-hapten sera solutions were
prepared by diluting the sera in DPBS (1:400, 1:800, or
1:600). Dialysis buffer was prepared by diluting the corre-
sponding negative sera in DPBS (1:400, 1:800, or 1:600).
Competitive inhibitors with different initial concentrations
were prepared in the dialysis buffer. For the test samples,
anti-hapten sera/D3-tracer was run against the negative sera/
inhibitors at the same sera dilution. A 100-μL aliquot of anti-
hapten sera containing 5 nM D3-tracer was pipetted into the
sample chamber, and a 300-μL aliquot of the competitive
inhibitor solution was added to the buffer chamber. For
negative controls, negative sera/D3-tracer was run against
the negative sera at the same sera dilution. A 100-μL
aliquot of negative sera containing 5 nM D3-tracer in
dialysis buffer was pipetted into the sample chamber,
and a 300-μL aliquot of the dialysis buffer was added
to the buffer chamber. Equilibrium dialysis and prepara-
tion of samples for UPLC/MS/MS was performed as de-
scribed above. In the absence of hapten antibodies (i.e.,
negative sera), there is no selective partitioning of the
D3-tracer in the sample chamber as all negative controls
have 0 % bound D3-tracer. After equilibrium, the total
concentration of the D3-tracer ([Tt]) for both test samples
and negative controls was ∼1.25 nM.
Determination of b values for 6-AM and morphine
Parameter b is the fraction of bound D3-tracer in the ab-
sence of competitive inhibitors. Anti-hapten sera/D3-tracer
was run against the negative sera at the same sera dilution.
Briefly, a 100-μL aliquot of anti-hapten sera containing
5 nM D3-tracer was pipetted into the sample chamber and
dialyzed against 300 μL of the appropriate dialysis buffer
(1:25, 1:50, 1:100, 1:200, 1:400, 1:800, 1:1600). Equilibri-
um dialysis and preparation of samples for UPLC/MS/MS
was performed as described above. The calculation of b
values is discussed (vide infra) as part of the Kd calculation
(see ESM Tables S1–S3).
Determination of % bound heroin
Since the hydrolysis of heroin in diluted sera was extensive,
the assay was performed in the presence of esterase inhibitors.
All sera were diluted in DPBS (1:400) and pretreated with
esterase inhibitors (iso-OMPA, 100 μM and BNPP, 100 μM)
for 1 h at 4 °C. Briefly, a 100-μL aliquot of pretreated dilute
sera with 5 nM heroin was pipetted into the sample chamber
and dialyzed against 300 μL of the dialysis buffer (1:400).
Equilibrium dialysis and preparation of samples for UPLC/
MS/MS was performed as described above. The % bound
heroin, which is the % heroin bound to the antibody in the
presence of esterase inhibitors, was calculated using the
equation:
% bound heroin ¼ heroin½ bound
heroin½ total
¼ heroin½ sample chamber− heroin½ buffer chamber
heroin½ sample chamber
 100
where [heroin]sample chamber and [heroin]buffer chamber are
the concentrations of heroin in the sample and buffer
chambers, respectively.
UPLC/MS/MS
The UPLC conditions and mass spectrometry parameters
were derived from Gottas et al. with some modifications
[27]. The amount of drugs in the sample and buffer chambers
was quantified using a Waters Acquity UPLC/TQD system
equipped with an Acquity HSS T3 column (2.1×100 mm,
1.8 μm particle size) maintained at 65 °C. Samples were
injected using full loop injection mode (10μL) and ran against
a 10-mM NH4HCOO pH 3.1/MeOH gradient (flow rate=
0.5 mL/min). The gradient profile is shown in ESM Table
S4. The total cycle time was 8 min to ensure column equili-
bration prior to the next sample. In addition, a weak wash
(600 μL, 10 % MeOH in H2O) and a strong wash (200 μL,
90 % ACN in H2O) were performed before each sample to
prevent carryover.
Positive ionization was performed in multiple reaction
monitoring (MRM) mode. The electrospray and source set-
tings were as follows: 0.7 kV (capillary voltage), 120 °C
(source temperature), 500 °C (desolvation temperature),
900 L/h (desolvation gas flow, N2), and 60 L/h (cone gas flow,
N2). The collision gas (Ar) flow in the collision cell was main-
tained at 0.4 mL/min. The unlabeled drug and D3-tracer were
differentiated based on their mass spectra (see ESM, Figs. S5–
S10). Drugs were identified by comparing the retention times
of the respective MRM transitions with the corresponding
standards. Data were processed in the QuanLynx™ software
and the drug concentrations in the sample and buffer chambers
were quantified using peak area.
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Calculation of apparent dissociation constant (Kd)
The Kd value can be calculated using Müller’s equation [23,
28]:
Kd ¼ I50½ − T t½ ð Þ 1−1:5bþ 0:5b2
 
[I50], which is the molar concentration of the competitive in-
hibitor required for 50 % inhibition, was derived through in-
terpolation on the % inhibition vs [I] curve. [Tt] is the total
molar concentration of the D3-tracer after equilibrium. The
fraction of bound D3-tracer (b) in the absence of competitive
inhibitor, I0, was calculated using the equation:
b ¼ D3‐tracer½ bound; I0
D3‐tracer½ total; I0
¼ D3‐tracer½ sample chamber− D3‐tracer½ buffer chamber
D3‐tracer½ sample chamber
where D3‐tracer½ bound; I 0 is the concentration of the D3-tracer
bound to the antibody in the absence of competitive inhibitor,
D3‐tracer½ total; I 0 is the total (bound + free) concentration of
the D3-tracer in the absence of competitive inhibitor, [D3-
tracer]sample chamber is the concentration of the D3-tracer in
the sample chamber, and [D3-tracer]buffer chamber is the concen-
tration of the D3-tracer in the buffer chamber.
For tight-binding antibodies, the b values of the anti-hapten
sera were from 0.4 to 0.7 even at high dilutions (1:400, 1:800,
and 1:1600). No binding was assigned for anti-hapten sera
with b values of ∼0 % at 1:25 dilution. The % inhibition at a
given concentration of the competitive inhibitor, [I], was cal-
culated using the equation:
% inhibition ¼ 100 1− D3‐tracer½ bound;I
D3‐tracer½ bound;I0
 !
D3‐tracer½ bound;I ¼ D3‐tracer½ sample chamber− D3‐tracer½ buffer chamber
where [D3-tracer]bound, I is the concentration of the D3-tracer
bound to the antibody in the presence of competitive inhibitor.
The Kd was not determined at ≤1:100 dilution due to degra-
dation of heroin, 6-AM, and morphine.
ELISA and competition ELISA
The pooled mice sera were derived from previous animal
studies [25, 29, 30]. ELISA was used to measure the serum
antibody levels at week 9 against the heroin haptens. Compe-
tition ELISA was used to assess the cross-reactivity of the
vaccine-induced anti-hapten sera to heroin and its major me-
tabolites: 6-AM and morphine. ELISA and competition
ELISA were performed as described previously [7]. The de-
tailed procedures for ELISA and competition ELISA were
provided in the ESM.
Data analysis
Statistical analysis was performed using GraphPad Prism Ver-
sion 6.0c. A t test (paired, two-tailed) was used to compare the
concentration of the sample and buffer chambers. A one-way
analysis of variance (ANOVA) with Tukey’s correction for
multiple comparisons was used to compare the Kd values de-
rived from different assay conditions and to compare the %
intact heroin after 24 h from different assay conditions. A one-
way ANOVAwith anti-DiPrOxyHap as the control group and
with Dunnett’s correction for multiple comparisons was used
to compare the % bound heroin.
Results
Synthesis of heroin hapten 6-AcMorHap
6-AcMorHap was synthesized from hydromorphone 1 using a
previously developed procedure for the introduction of the C-
3 nitro group (Fig. 2) [25, 31]. Triflation of the C-3 phenol
with N-phenyl-trifluoromethansulfonamide followed by pal-
ladium-mediated reductive cleavage afforded arene 3 in
excellent yield. Direct C-3 nitration was stymied by un-
desired C-1 regioselectivity of the nitration. Instead, chlo-
rination of the more reactive C-1 position with N-
chlorosuccinimide allowed for selective C-3 nitration un-
der mild conditions to give nitro compound 5 in moderate
yield [32]. The C-6 ketone was reduced with K-selectride
to give alcohol 6. Reduction of the nitro group was af-
fected via palladium-catalyzed hydrogenation under acidic
conditions, and it proceeded smoothly with concomitant
cleavage of the C-1 chlorine to give amino alcohol 7. The
aniline was selectively acylated with 2,5-dioxopyrrolidin-
1-yl 3-(tritylthio)propanoate 8 to give amide 9 [33]. Fi-
nally, acylation of the hydroxyl moiety (Ac2O, DMAP)
afforded heroin hapten 6-AcMorHap in 23 % over eight
steps. The syntheses of 6-PrOxyHap, MorHap, DiAmHap,
and DiPrOxyHap have been published [25, 30].
Equilibration of D3-morphine and morphine
The dialysis cassette consists of two chambers separated by a
semipermeable membrane. The D3-tracer was added to the
sample chamber while the competitive inhibitor was added
to the buffer chamber. D3-morphine (5 nM, sample chamber)
and morphine (1333.3 nM, buffer chamber) were allowed to
diffuse in the semipermeable membrane (Fig. 3a, b). At 3 h,
59.68±2.00 and 40.32±2.00 % of D3-morphine partitioned
into the sample and buffer chambers, respectively (Fig. 3a),
and this difference between the % D3-morphine in the two
chambers was significant (**p<0.01, t test). There was no
significant difference in D3-morphine concentrations between
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the sample and buffer chambers at 6, 12, and 24 h (p=not
significant, t test). Also at 3 h, 45.32±0.70 and 54.66±
0.70 % of morphine partitioned into the sample and buffer
chambers, respectively (Fig. 3b, **p<0.01, t test). The
amount of morphine that partitioned into the sample chamber
increased over time thereby decreasing the difference between
the two chambers: 46.68±0.17 % (6 h, *p<0.05), 48.59±
0.39 % (12 h, *p<0.05), and 49.97±2.3 % (24 h, no signifi-
cant difference compared to the buffer chamber). Based on
these data, 24 h was selected as the standard time of
incubation.
Stability of the drugs in dilute sera
The degradation of heroin, 6-AM, and morphine was exam-
ined at different dilutions of the normal mouse sera for 24 h
(Fig. 3c–e). There was an extensive hydrolysis of heroin at all
dilutions (Fig. 3c). Thus, the calculation of antibody affinity
against heroin was not performed. Hydrolysis of 6-AM was
not observed at ≥1:200 dilutions (Fig. 3d). Degradation of
morphine was not observed at ≥1:100 dilutions (Fig. 3e).
Based on stability data and b values (vide infra), the calcula-
tion of antibody affinity against 6-AM and morphine was
performed at ≥1:400 dilution.
Apparent dissociation constant of a monoclonal antibody
standard
The Kd of ab1060 at different concentrations of the antibody
and the D3-morphine was determined (Table 1). Additionally,
parameter b, defined as the fraction of the D3-tracer bound to
the antibody in the absence of competitive inhibitor, was also
considered for the assessment of Kd values. The Kd (1.96±
0.17 nM) derived from the assay condition with b=0.41 was
consistent with the reportedKd (2 nM) [34]. Although ED and
UPLC/MS/MS have been individually considered as standard
methods, this result confirms that the combination of compe-
tition ED-UPLC/MS/MS can be accurately used for drug-
antibody binding quantification. A dramatic reduction in Kd
was calculated when b values were outside of this range
(Table 1). The results were consistent with the studies ofMüll-
er that the performance of competition ED must be done at
assay conditions with b values of 0.4–0.7 [23].
Opiate affinities of vaccine-induced antibodies
by competition ED
For accurate determination of antibody affinity to 6-AM and
morphine, the Kd was derived from different dilutions of
Fig. 3 Equilibration of D3-
morphine and morphine in
dialysis cassettes (a, b). D3-
morphine was added to one side
(sample chamber) of the dialysis
cassette and morphine to the other
side (buffer chamber). D3-
morphine and morphine
concentrations reached
equilibrium after 6 and 24 h,
respectively. Drug concentrations
between the two chambers were
compared using paired t test
(**p<0.01, *p<0.05). Stability of
heroin, 6-AM, and morphine in
the absence of sera or in the
presence of sera at different sera
dilutions in DPBS, pH 7.4 at 4 °C
(c–e). Samples were incubated for
the time indicated. No
degradation of 6-AM and
morphine was observed in the
absence of sera. Partial heroin
hydrolysis (∼20 %) was observed
even in the absence of sera (also
shown in Fig. 4a). Opiates were
quantified by UPLC/MS/MS.
Values are the mean of triplicate
determinations±standard
deviation
Affinities of antibodies induced by hapten bioconjugates for drugs of abuse 1197
pooled sera, which were obtained by immunization of the
indicated hapten conjugated to TT and mixed with liposomal
monophosphoryl lipid A as adjuvant (Table 2 and ESM
Fig. S4) [25, 29, 30, 35]. In general, there was no statistical
difference in Kd values when the assay conditions had a b
value between 0.4 and 0.7 (ESM Tables S1 and S2). Antibod-
ies to hapten conjugates 6-AcMorHap, 6-PrOxyHap, and
MorHap had high affinities (Kd<5 nM) to 6-AM and mor-
phine (Table 2). Anti-6-AcMorHap had significantly higher
affinities for both 6-AM and morphine relative to anti-6-
PrOxyHap (p<0.05, one-way ANOVA). Although anti-6-
PrOxyHap and anti-MorHap had similar affinities to mor-
phine, the affinity of anti-6-PrOxyHap to 6-AM was signifi-
cantly higher than anti-MorHap (p<0.01, one-way ANOVA).
Both anti-DiAmHap and anti-DiPrOxyHap had low affinity
for 6-AM and no affinity to morphine. In competition ED, low
affinity and no binding were both determined in 1:25 sera
dilution also to ensure that the lack of drug-antibody binding
was not due to low concentration of the antibody, but due to
the affinity of antibody for the drugs. Low affinity is defined
as when >5 % of the D3-tracer was bound to the anti-hapten
sera at a 1:25 sera dilution but was <5 % at 1:400. No binding
is defined as when <5 % of the D3-tracer was bound to the
anti-hapten sera at 1:25 sera dilution. Antibodies to DiAmHap
and DiPrOxyHap bound 61.5±2.3 and 9.1±1.9 % D3-6-AM,
respectively, at 1:25 sera dilution. However, the Kd cannot be
accurately calculated because 6-AMwas relatively unstable at
1:25 sera dilution (Fig. 3d). Both anti-DiAmHap and anti-
DiPrOxyHap had 0 % binding to D3-morphine at all dilutions
(ESM Tables S2 and S3). At 1:400 sera dilution, preimmune
sera (week 0) do not bind D3-6-AM and D3-morphine,
confirming that plasma proteins were not binding the opiates
used in this study.
Binding of heroin to vaccine-induced antibodies
The Kd of polyclonal antibodies to heroin cannot be measured
by competition ED-UPLC/MS/MS utilizing D3-heroin because
of the extensive degradation of heroin in dilute sera. By extrap-
olation of the heroin stability data during ED with 1:400 sera
dilution (Figs. 3c and 4a), heroin, D3-heroin, 6-AM, and D3-6-
AMwould be present at equilibrium with 6-AM and D3-6-AM
as predominant chemical species. Although Kd cannot be accu-
rately calculated, the assessment of heroin binding to polyclonal
antibody is feasible if sufficient concentration of heroin is pres-
ent in the assay. After 24 h, 79.9±2.71% heroin remained intact
in DPBS (Fig. 4a). This observation was consistent with a pre-
vious report on the spontaneous hydrolysis of heroin at physi-
ological pH [36]. This indicates that assay conditions must be
identified such that the degradation of heroin in given serum
dilution is comparable to spontaneous hydrolysis of heroin in
buffer. The effect of inhibitors (I) on the stability of heroin was
determined bymeasuring% intact heroin after 24 h in DPBS (−
Sera), in dilute sera (+ Sera), and in dilute sera in the presence of
OMPA/BNPP (+ Sera/I). The inhibitors did not suppress the
spontaneous hydrolysis of heroin in buffer (p=not significant,
one-way ANOVA) but did inhibit the extensive degradation of
heroin in sera (****p<0.0001, one-wayANOVA). The binding
of heroin to anti-hapten sera was measured in the presence of
inhibitors because the inhibitors blocked the serum esterase-
mediated heroin degradation allowing for appreciable heroin
concentrations that can be measured under these assay condi-
tions. ED performed in the presence of these inhibitors showed
that anti-6-AcMorHap, anti-6-PrOxyHap, anti-MorHap, and
anti-DiAmHap bound significantly higher amount of heroin
with 92.89±0.72 % (****p<0.0001), 76.66±2.17 %
(****p<0.0001), 13.82±4.66 % (**p<0.01), and 10.75±5.34
(*p<0.05, one-way ANOVA), respectively, relative to anti-
DiPrOxyHap (1.54±2.66 %) (Fig. 4b, multiple comparisons
using one-way ANOVA).
Opiate affinities of vaccine-induced antibodies
by competition ELISA
The most commonly used method for measuring the affinity
of anti-hapten sera to small molecules has been competition
ELISA because of its facile nature. In competitive ELISA,
binding affinity is reported in terms of 50 % inhibition con-
centration (IC50). Analysis of the anti-hapten sera by compe-
tition ELISA indicated that anti-6-AcMorHap and anti-6-
PrOxyHap had the highest relative affinities (IC50<10 μM)
to heroin, 6-AM, and morphine (Table 3 and ESM Fig. S11).
Anti-MorHap showed more modest affinity (IC50∼21 μM) to
6-AM, higher affinity for morphine (9.2 μM), and no affinity
Table 2 Kd of pooled sera from mice immunized with different TT-
hapten conjugates






DiAmHap Low affinityb No bindingc
DiPrOxyHap Low affinityb No bindingc
a AllKd values were calculated from the data shown in ESMFig. S4 using
Müller’s equation and are the mean of triplicate determinations±standard
deviation (see ESM, Tables S1 and S2). The affinities of anti-6-
AcMorHap, anti-6-PrOxyHap, and anti-MorHap for 6-AM are different
(multiple comparisons using one-way ANOVA). The affinities of anti-6-
PrOxyHap and anti-MorHap for morphine are similar and are different to
anti-AcMorHap (multiple comparisons using one-way ANOVA)
b >5 % of the D3-tracer was bound to the anti-hapten at 1:25 sera dilution
but was <5 % at 1:400 dilution (see ESM, Table S1 and S3)
c <5 % of the D3-tracer was bound to the anti-hapten at 1:25 sera dilution
(see ESM, Tables S2 and S3)
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(IC50>10
3 μM) to heroin. Anti-DiAmHap had no affinity for
heroin and its metabolites. Anti-DiPrOxyHap displayed mod-
est affinity to heroin, lower affinity to 6-AM (IC50∼145 μM),
and no affinity to morphine. Comparison of these affinities
with those obtained by competition ED-UPLC/MS/MS indi-
cated that the affinity (IC50) derived from competition ELISA
underestimated the actual Kd value by a factor of 10
3–104.
Competition ELISA did not determine if the antibodies bind
the drug of interest or if the degradation product was respon-
sible for the binding (i.e., heroin degrading to 6-AM).
Discussion
Drugs of abuse are too small to elicit antibody production and,
therefore, require conjugation of structural analogs (haptens)
to immunogenic proteins [37, 38]. Hapten bioconjugate vac-
cines are frequently used to generate functional antibodies
against small molecules. The chemical structure of the hapten
generally dictates the cross-reactivity of the anti-hapten sera,
and thus, the hapten surrogate must be rationally designed [30,
39, 40]. To be efficacious, the hapten antibodies must cross-
react with high affinity to the target drug(s).
For heroin vaccines, the hapten design must mimic the key
epitopes of heroin and its metabolites [4]. Currently, there has
been no established rule that predicts whether a given hapten
design would induce anti-hapten sera that target multiple
chemical structures. To better understand the relationship be-
tween structure and cross-reactivity, the binding affinity of the
antibodies induced by immunization with heroin haptens 6-
AcMorHap, 6-PrOxyHap, MorHap, DiAmHap, and
DiPrOxyHap conjugated to TT (Fig. 2) was assessed using
competition ED-UPLC/MS/MS and competition ELISA
(Fig. 5). We hypothesized that these hapten designs will in-
duce antibodies with different cross-reactivities that will guide
the future optimization of hapten structure. In terms of linker
point attachment, the hapten design can be assigned into three
groups: C3-linked haptens (6-AcMorHap and 6-PrOxyHap),
C6-linked hapten (MorHap), and N-linked haptens
(DiAmHap and DiPrOxyHap). The importance of linker point
attachment was previously discussed by Matyas’ concept on
facial recognition [30]. The conjugation of the haptenic surro-
gates to TT confines their freedom of motion, and thus, the
hapten’s molecular structure bisects into two immunologically
defined Bfaces.^ The Bfront face^ is defined as the key epi-
topes exposed to the immune system, while the Bback face^ is
the sterically blocked moieties that cannot induce antibodies.
Using the concept of facial recognition, 6-AcMorHap is par-
ticularly interesting because it preserves the C6-ester group
Fig. 4 Assessment of the anti-hapten binding to heroin. Percent of intact
heroin after 24 h in buffer with no sera (− Sera, DPBS), with sera (+ Sera,
1:400 sera dilution inDPBS), andwith sera and inhibitors (+ Sera/I, 1:400
sera dilution in DPBS containing the esterase inhibitors iso-OMPA/
BNPP) (a). Percent heroin in − Sera and + Sera/Iwas similar and different
from + Sera (****p<0.0001, multiple comparisons using one-way
ANOVA). Percent of heroin that was bound to anti-hapten sera in the
presence of iso-OMPA/BNPP (b). Percent bound heroin was different
from anti-DiPrOxyHap sera (****p<0.0001, **p<0.01, *p<0.05,
multiple comparisons using one-way ANOVA). Opiates were quantified
by UPLC-MS/MS. Sera from week 9 (3 weeks after two immunizations)
from five mice per group were pooled and used in the assays. Values are
the mean of triplicate determinations±standard deviation
Table 3 Antibody titer and IC50 calculated using competition ELISA
of pooled sera frommice immunized with different TT-hapten conjugates




6-AcMorHap 819,200 0.5 1.1 0.1
6-PrOxyHap 409,600 2.2 7.5 1.6
MorHap 1,638,400 >1000 21.41 9.182
DiAmHap 204,800 >1000 >1000 >1000
DiPrOxyHap 102,400 16.8 144.9 >1000
a Binding ELISAwas done against BSA-hapten coating antigen
bAll IC50 values were calculated from competition ELISA data shown in
ESM Fig. S11 using nonlinear regression log [inhibitor] vs. normalized
response model
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that is the common moiety for both heroin and 6-AM [30].
Animals immunized with C3-linked hapten conjugates in-
duced antibodies that bind morphine [41, 42]. In contrast to
6-AcMorHap, the haptens that were used by Spector and
Koida contain a C6-alcohol group. We hypothesized that 6-
AcMorHap has a Bfront face^ that mimics heroin, 6-AM, and
morphine, and thus, TT-6-AcMorHap bioconjugates will in-
duce antibodies that cross-react with these three drugs
(Fig. 1a, b) [30]. We also hypothesized that modification of
an acetyl group to a propan-2-one group at the C6 position
(i.e., 6-PrOxyHap) will reduce the binding affinity, but will
not change the pattern of cross-reactivity because haptens 6-
AcMorHap and 6-PrOxyHap have similar overall molecular
shapes. Previously, wewere not able to accurately measure the
affinity of the anti-hapten sera due to the inherent limitations
of competition ELISA [30]. Now that we can more accurately
measure the affinity, we are able to demonstrate that our hy-
pothesis of facial recognition has greater relevance [30].
In this study, competition ED utilizing D3-tracers has been
developed to address the inherent constraints of competition
ELISA. The main challenge in ED is to maintain the stability
of the heroin and its metabolites during the assay. To address
this problem, the equilibration time and the degradation of the
drugs in dilute sera were investigated. Equilibration between
the competitive inhibitor and the D3-tracer were attained at
24 h (Fig. 3a, b). However, this long equilibration time is
not compatible with the short half-life of heroin and its me-
tabolites in Bneat^ sera. We believed that by diluting the
mouse sera, the concentration of the enzymes involved in
heroin metabolism would be reduced. Consequently, the deg-
radation of heroin and its metabolites would be suppressed.
The degradation of the drugs in different dilutions of the sera
was monitored for 24 h (Fig. 3c–e). At all dilutions, extensive
degradation of heroin was observed. This suggests that the
activity of the esterases, which are responsible for C3-ester
group cleavage, cannot be suppressed by simple dilution. Af-
ter 24 h, degradation of 6-AM and morphine was observed at
lower dilutions but not at higher dilutions of sera. This indi-
cates that the activity of the enzymes responsible for C6-ester
group hydrolysis is concentration dependent. In general, mor-
phine metabolism occurs in the liver. However, extrahepatic
metabolism of morphine has been also reported [43]. The
degradation profiles of the drugs seem to reach a plateau after
12 h, which might be due to loss of enzymatic activity. Col-
lectively, ≥1:400 sera dilutions can be used to measure anti-
body affinities to 6-AM and morphine but not to heroin.
Another challenge that must be addressed in ED is the
potential impact of plasma protein binding of the drugs. Re-
cently, Zhang et al. reported the plasma protein binding of 222
drugs, of which 50 % showed 90–100 % binding [44]. In
Bneat^ plasma/sera, heroin and morphine have ∼35 % plasma
binding [45]. Presumably, 6-AMwill also have ∼35% plasma
binding due to structural similarity to both drugs. If the bind-
ing of the D3-tracers to plasma protein is significant, the dis-
tinction of bonafide antibody-drug interactions from nonspe-
cific protein binding becomes challenging. However, we be-
lieved that the effect of plasma binding could be reduced by
sera dilution. At ≥1:400 dilution of the week 0 sera (i.e.,
preimmunized sera), D3-6-AM and D3-morphine showed
∼0 % binding to the plasma proteins. The binding of heroin
to plasma proteins cannot be accurately assessed due to
esterase-mediated degradation of heroin in dilute sera. How-
ever, extrapolation of the % bound heroin for anti-
DiPrOxyHap sera conveys that the binding of heroin to plas-
ma proteins is negligible in 1:400 sera dilution (Fig. 4b). Col-
lectively, these data suggest that competition ED-UPLC/MS/
MS can be used to measure antibody affinities to 6-AM and
morphine in the dilute sera. For other drugs, where plasma
protein binding is still significant even in dilute sera, the Kd
values would difficult to calculate.
Fig. 5 Comparison of competition ED and competition ELISA. In this
example, the affinity of the anti-6-AcMorHap to 6-AM is measured. For
competition ED, 6-AM is allowed to equilibrate with D3-6-AM/anti-6-
AcMorHap. At equilibrium, the amount of drugs in both chambers is
quantified by UPLC/MS/MS (left panel). For competition ELISA, the
ELISA plate wells are precoated with bovine serum albumin (BSA)-6-
AcMorHap and subsequently incubated with anti-6-AcMorHap. 6-AM is
allowed to disrupt the BSA-6-AcMorHap/anti-6-AcMorHap interactions
(right panel). The synthesis of BSA-6-AcMorHap was described in the
ESM and Fig. S12
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We tested the applicability of the competition ED-UPLC/
MS/MS method for evaluating small drug-antibody interactions
by measuring the dissociation constant of commercially avail-
able morphine monoclonal antibody ab1060. According to
Müller, competition equilibrium dialysis should be carried out
under the following conditions: (1) the b value of the antibody/
tracer system should be ∼0.4–0.7, and (2) the specific radioac-
tivity of the tracer should be optimal to prevent large deviations
in the antibody affinity [23]. The effects of b values and D3-
morphine concentrations onKd were investigated using different
assay conditions. Our results were consistent with the findings
of Müller. A Kd of 1.96 nM, which is in agreement with the
reported value of 2 nM [34], is obtained for ab1060 when b is
0.41 (Table 1 and ESM Fig. S4). At 2.4 nM ab1060/2.5 nMD3-
morphine, a large deviation inKd was observed. Thismost likely
was because b was >0.7 and 2.5 nM D3-morphine was not an
optimal tracer concentration. Considering the accuracy of affin-
ity is dependent on both b values and specific concentration of
the tracer, we utilized the b limit range of 0.4–0.7 and 5 nMD3-
tracer for determining the Kd values of the anti-hapten sera.
Since antibody concentration is not required for the calcu-
lation of affinity, the competition ED-UPLCMS/MS could be
extended to polyclonal sera [23]. As the polyclonal sera have
high antibody titer (Table 3), we hypothesized that the con-
centration of hapten antibodies in dilute sera is still amenable
for binding studies. The b values of anti-hapten sera were
determined at both low and high sera dilutions (ESM
Tables S1–S3). Anti-6-AcMorHap, anti-6-PrOxyHap, and
anti-MorHap had b values of 0.4–0.7 at the range of 1:400–
1:1600 dilutions. This suggests that Kd for 6-AM and mor-
phine can be only calculated within a specific dilution range.
At low sera dilution (≤1:100), 6-AM and morphine were
prone to degradation, while at high sera dilution (≥1:1600, b
<0.4), the concentration of antibody was insufficient for reli-
able quantification. Anti-6-AcMorHap, anti-6-PrOxyHap,
and anti-MorHap bound 6-AM and morphine with Kd values
of <5 nM (Table 2 and ESM Fig. S4). Both anti-DiAmHap
and anti-DiPrOxyHap have low affinity for 6-AM and no
affinity for morphine. In contrast to the affinity values derived
from ab1060, the Kd values of anti-hapten sera were not prone
to large deviations when b≥0.7. Based on the results, Bpure^
monoclonal antibody was more sensitive to variation in Kd,
when the b values were outside of the limit range. As the study
of Müller was performed using anti-hapten polyclonal sera,
the b limits of 0.4–0.7 might have limitations when applied to
monoclonal antibodies. It is also possible that the optimal
range of b values and D3-tracer concentrations vary from a
given specific monoclonal antibody/drug system to another,
and therefore, these values have to be determined empirically.
In the case of the polyclonal anti-hapten sera that were used in
this study, the b limit range of 0.4–0.7 was congruent with the
findings of Müller, and the 5-nM D3-tracer concentration was
optimal enough to prevent large deviation in Kd values.
To suppress the hydrolysis of heroin at 1:400 sera dilution,
the specific esterase inhibitors iso-OMPA and BNPP were
added to the reaction mixture [46–48]. The addition of iso-
OMPA and BNPP increased the amount of intact heroin to
≥80 %, which was comparable to hydrolysis of heroin in
DPBS in the absence of sera (Fig. 4a). This suggests that
although Kd could not be calculated, the amount of % bound
heroin to the antibody in lieu of Kd could be used to assess
binding. Anti-6-AcMorHap and anti-6-PrOxyHap had 92.89
±0.72 and 76.66±2.17 % of the heroin bound, respectively
(Fig. 4b), suggesting that hapten designs 6-AcMorHap and 6-
PrOxyHap can mimic crucial epitopes of heroin.
While competition ED is a solution-based assay, competi-
tion ELISA depends on interactions at the solid-liquid inter-
face (Fig. 5). In contrast to the competition ED-UPLC/MS/
MS method, the IC50 values calculated from competition
ELISA were in the micromolar range, which suggest low af-
finity antibodies (Table 3 and ESMFig. S11). Collectively, the
IC50 values derived from competition ELISA were 10
3–104
higher than the Kd from competition ED-UPLC/MS/MS.
However, we believe that these IC50 values are not true reflec-
tions of drug-antibody interactions. In competition ELISA,
hapten-antibody interactions occur at the solid-liquid interface
and, thus, are prone to avidity effects. It could be envisioned
that the two arms of the IgG antibodies were tightly engaged
to the haptens of the coating antigen; thus, higher concentra-
tions of the competing drugs are needed to disrupt the hapten-
antibody interactions. Besides underestimation of antibody
affinity (i.e., high IC50), another limitation associated with
competition ELISA is ambiguity in the interpretation of re-
sults. In the case of anti-DiAmHap, there are at least two
interpretations for IC50 >10
3 μM. As we originally proposed
for anti-DiAmHap and anti-DiPrOxyHap, either the hapten
antibodies simply do not cross-react with the competing
drugs, or the affinity of the hapten antibodies to the original
hapten design is extremely high [25, 30]. The latter interpre-
tation is consistent with our previous findings [30] and the
findings of Pravetoni et al., which demonstrated the higher
affinity of hapten antibodies to haptenic surrogate than the
target drugs [15]. In addition, the avidity effects associated
with competition ELISA further increase the interactions be-
tween the haptenic surrogate and the hapten antibodies. This
ambiguity can be resolved by considering the b values derived
from competition ED-UPLC/MS/MS (ESM Tables S1–S3).
Extending those findings, the IC50 values of anti-DiAmHap
and anti-DiPrOxyHap to 6-AM and morphine are simply due
to weak drug-antibody interactions.
Although there was an underestimation of binding affini-
ties (i.e., high IC50) with competition ELISA [14], it is note-
worthy to mention that both methods gave similar trends, i.e.,
polyclonal antibody with high binding affinities for heroin, 6-
AM, and morphine was consistently predicted by both
methods. In light of the results, we have observed recurring
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themes that could serve as guiding principles in the design of a
heroin vaccine (Fig. 1b). First, when linker is at the C3 posi-
tion, the induced antibodies (anti-6-AcMorHap and anti-6-
PrOxyHap) cross-reacted with heroin, 6-AM, and morphine.
Second, when linker is at the C6 position, the induced anti-
bodies (anti-MorHap) cross-reacted with both 6-AM and mor-
phine, but poorly with heroin. Third, when the linker is at the
bridge nitrogen, the induced antibodies (anti-DiAmHap and
anti-DiPrOxyHap) had low cross-reactivity to both 6-AM and
morphine. Heroin contains two acetyl groups at the C3 and C6
position, while DiAmHap and DiPrOxyHap have acetamide
and propan-2-one groups, respectively. The binding affinity
data suggest that modifications at this position dramatically
affect the cross-reactivity of the induced antibodies to heroin.
These results are in agreement with previous reports that hy-
drolytically stable N-linked haptens tended to generate anti-
bodies that were highly specific to the parent hapten and had
no cross-reactivity to other drugs [49–52]. It has been postu-
lated that antibody titer and antibody affinity are crucial for the
efficacy of drug of abuse vaccines [1, 2]. Previously, we dem-
onstrated that mice immunized with TT-DiAmHap and TT-
DiPrOxyHap showed partial protection and no protection
against heroin challenge, respectively [25, 30]. In terms of
binding affinity, anti-DiAmHap is superior to anti-
DiPrOxyHap (Fig. 4b and ESM Table S3). The protection
against heroin challenge could be attributed to the presence
of high titer, but low affinity antibodies to heroin and 6-AM.
Based on IC50 and antibody titer from ELISA and Kd and %
heroin bound from competition ED-UPLC/MS/MS, it is clear
that 6-AcMorHap and 6-PrOxyHap are the lead hapten
designs.
Despite the ability of competition ED-UPLC/MS/MS to
measure Kd, the assay system does have some limitations.
Due to the use of dilute sera, the method cannot measure the
affinity of polyclonal antibodies that poorly bind 6-AM and
morphine. Within the context of a heroin vaccine, it can be
argued that the determination of antibodies with high Kd
values (>1 μM, low affinity antibodies) is unimportant, since
these antibodies are expected to bind low amounts of heroin
and its metabolites and, consequently, have little role in effi-
cacy. The competition ED-UPLC/MS/MS also cannot be used
for drugs that have a significant binding to plasma proteins
even at high sera dilutions. Overall, competition ED-UPLC/
MS/MS is a simple method for determining the binding affin-
ities of antibodies. It is a convenient method because it does
not involve the use of radioactive tracers, and all the reagents
for the assay are commercially available. This nonradioactive
method only requires 5–10 μL of anti-hapten sera to generate
a binding curve and has the potential applications for studying
the binding affinities of antibodies induced by small molecule
hapten-based immunogens. In addition, competition ED-
UPLC/MS/MS resolved the ambiguity of the IC50 values de-
rived from competition ELISA.
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